Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Protara Therapeutics (Nasdaq: TARA) granted inducement equity awards to a newly hired employee under Nasdaq Listing Rule 5635(c)(4).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Protara Therapeutics (Nasdaq: TARA) granted inducement equity awards to a newly hired employee under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee approved 10,200 stock options (exercise price $7.04) granted on Feb 2, 2026 and 5,100 RSUs with a grant date of Apr 1, 2026.
Options vest over four years (25% at one year, then monthly over 36 months). RSUs vest over three years in three equal annual installments, subject to continued service.
Details
News Market Reaction – TARA
On Feb 3, the first trading day after this news, TARA closed 4.12% below the previous close.
Data tracked by StockTitan Argus for the Feb 3 session.
Key Figures
- Inducement stock options
- 10,200 options
- Granted to one new employee under Inducement Plan
- Inducement RSUs
- 5,100 RSUs
- Granted to one new employee under Inducement Plan
- Option exercise price
- $7.04 per share
- Closing trading price on February 2, 2026 grant date
- Option vesting cliff
- 25%
- Vests on one-year anniversary of option grant date
- Post-cliff option vesting
- 1/36 monthly
- Remaining option shares vest monthly over 36 months
- RSU vesting term
- 3 years
- RSUs vest in three equal annual installments
- RSU grant date
- April 1, 2026
- Grant date for inducement RSU awards
- Stock price vs 52-week high
- -9.46%
- Current price relative to $7.82 52-week high
Historical Context
-
Planned presentation of updated Phase 2 ADVANCED-2 data in NMIBC at ASCO GU.
-
Highlighted 2026 milestones and an ~$86M offering extending cash runway into 2028.
-
Announcement of participation in the 44th J.P. Morgan Healthcare Conference.
-
First patient dosed in Phase 3 THRIVE-3 IV Choline Chloride trial for PS patients.
-
FDA Breakthrough Therapy and Fast Track designations for TARA-002 in pediatric LMs.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
non-qualified stock options financial
restricted stock units (rsus) financial
exercise price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (“Protara” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced the recent grants of inducement non-qualified stock options and restricted stock units (RSUs) to one newly-hired employee.
The Compensation Committee of Protara’s Board of Directors approved an aggregate of 10,200 stock option awards and 5,100 RSU awards to one new employee from the Inducement Plan, as inducements material to the new employee’s employment in accordance with Nasdaq Listing Rule 5635(c)(4). Such option awards were granted on February 2, 2026 and have an exercise price of
All option awards vest over four years, with
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin (BCG), as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
Source: Protara Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.